Beam Therapeutics to Participate in Upcoming May Investor Conferences
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following May investor conferences: Barclays Virtual Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023 at 11:05 a.m. ET;Stifel 2023 Tailoring Genes: Virtual Genetic Medicines on Tuesday, May 30, 2023 at 10:20 a.m. ET. Live webcasts will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manu
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects [Seeking Alpha]Seeking Alpha
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV [Forbes]Forbes
BEAM
Earnings
- 2/27/24 - Beat
BEAM
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- BEAM's page on the SEC website